Medisse raises $3.5M for new med device biomaterial


Medisse in The Netherlands attracted $3.5 million in new Series B equity funding, money that will come in handy as the company develops its FlexiSurge adhesion barrier. Medisse, first launched in 2009, develops resorbable soft tissue-related implants that are based on a flexible material. Plans call for using the funds to launch a proof of concept clinical trial for FlexiSurge, with a goal of obtaining a CE mark. The latest investment round drew one new investor--IIG--along with previous investors BioGeneration Ventures and Omnes Capital. As part of the deal, the Dutch Ministry of Economic Affairs also issued an innovation credit, the company notes. Item

Filed Under